Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Carbain B, Bayliss R, Boxall K, Coxon C, Lebraud H, Matheson C, Turner D, Zhen-Wang L, Griffin RJ. 2-arylamino-6-ethynylpurines as Potent Irreversible Inhibitors of the Mitotic Kinase Nek2. In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2012, Dublin, Ireland: Pergamon.
• Chen L, Tweddle DA. p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Frontiers in Oncology 2012, 2, 173.
• Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, Delattre O, Delorenzi M, Shipley J. PAX3/FOXO1 Fusion Gene Status is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. Journal of Clinical Oncology 2012, 30(14), 1670-1677.
• Pal D, Rigas AC, Williamson SC, Moad M, Carr-Wilkinson J, Lako L, Robson CN, Heer R. Induced pluripotent stem cell (iPSC) re-programming in the human prostate. In: Annual Meeting of the Society of Academic and Research Surgery. 2012, Nottingham, UK: John Wiley & Sons Ltd.
• Heer R, Glendinning RJ, Nesbitt CN, Pal D, Rix D, Menezes P, Johnson MI. Secondary haemorrhage following transurethral resection of bladder tumour — is it always related to infection?. British Journal of Medical and Surgical Urology 2012, 5(2), 61-66.
• Pal D, Rigas AC, Williamson SC, Moad M, Robson CN, Heer R. The role of epithelial to mesenchymal transition (EMT) in iPS induction of human prostate. In: Annual Meeting of the Society of Academic and Research Surgery. 2012, Nottingham, UK: John Wiley & Sons Ltd.
• Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow LJ, Fordham SE, Forster VJ, Jackson G, Bomken S, Jones G, Allan JM. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 2012, 119(1), 196-205.
• Tudhope SJ, Wang CC, Petrie JL, Potts L, Malcomson F, Kieswich J, Yaqoob MM, Arden C, Hampson LJ, Agius L. A Novel Mechanism for Regulating Hepatic Glycogen Synthesis Involving Serotonin and Cyclin-Dependent Kinase-5. Diabetes 2012, 61(1), 49-60.
• Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ, NCRI Haematology Oncology Studies. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012, 26(2), 349-355.
• Williamson D, Clifford S. A significant proportion of medulloblastoma do not sub-group robustly: Identification of a molecular NOS (not otherwise specified) subgroup. In: 15th International Symposium on Pediatric Neuro-Oncology (ISPNO). 2012, Toronto, Canada: Oxford University Press.
• Veeratterapillay R, Simren R, El-Sherif A, Johnson MI, Soomro N, Heer R. Accuracy of the revised 2010 TNM classification in predicting the prognosis of patients treated for renal cell cancer in the north east of England. Journal of Clinical Pathology 2012, 65(4), 367-371.
• Forster V, Beyerle A, Heidenreich O, Allan J. AML1/ETO Confers a Mutator Phenotype in AML. In: Annual Meeting of the Kind-Philipp Foundation for Leukemia Research. 2012, Wilsede, Germany: Georg Thieme Verlag.
• Keen H, Pichler B, Kukuk D, Duchamp O, Raguin O, Shannon A, Whalley N, Jacobs V, Bales J, Gingles G, Ricketts S-A, Wedge SR. An evaluation of 2-deoxy-2- [18F]fluoro-D-glucose and 3‟-Deoxy-3‟-[18F]-fluorothymidine uptake in human tumor xenograft models. Molecular Imaging and Biology 2012, 14(3), 355-365.
• Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross PA, Plummer ER, Robson CN, Edmondson RJ. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecologic Oncology 2012, 124(1), 142-147.
• Robertson AGN, Krishnan A, Ward C, Pearson JP, Small T, Corris PA, Dark JH, Karat D, Shenfine J, Griffin SM. Anti-reflux surgery in lung transplant recipients: outcomes and effects on quality of life. The European Respiratory Journal 2012, 39(3), 691-697.
• Elliott PR, Irvine AF, Jung HS, Tozawa K, Pastok MW, Picone R, Badyal SK, Basran J, Rudland PS, Barraclough R, Lian LY, Bagshaw CR, Kriajevska M, Barsukov IL. Asymmetric Mode of Ca²⁺-S100A4 Interaction with Nonmuscle Myosin IIA Generates Nanomolar Affinity Required for Filament Remodeling. Structure 2012, 20(4), 654-666.
• Swaminathan S, Kang HN, Harvey RC, Huang CX, Buchner M, Chen ZS, Geng HM, Hall A, Igarashi K, Carroll WL, Willman CL, Melnick A, Muschen M. BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Pfaff E, Witt H, Jones DTW, Ryzhova M, Cho YJ, Wittmann A, Benner A, Weiss WA, von Deimling A, Scheurlen W, Kulozik AE, Clifford SC, Collins VP, Westermann F, Taylor MD, Lichter P, Pfister SM. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica 2012, 123(4), 515-527.
• Britton KM, Eyre R, Harvey IJ, Stemke-Hale K, Browell D, Lennard TWJ, Meeson AP. Breast cancer, side population cells and ABCG2 expression. Cancer Letters 2012, 323(1), 97-105.
• Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma. Lancet 2012, 379(9822), 1234-1244.
• Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, Brock P, Ladenstein R, Vassal G. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. European Journal of Cancer 2012, 48(16), 3063-3072.
• Bui C, Barter MJ, Scott JL, Xu Y, Galler M, Reynard LN, Rowan AD, Young DA. cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis. FASEB Journal 2012, 26(7), 3000-3011.
• Veeratterapillay R, Rakhra S, El-Sherif A, Johnson M, Soomro N, Heer R. Can the Kattan nomogram still accurately predict prognosis in renal cell carcinoma using the revised 2010 tumor-nodes-metastasis reclassification?. International Journal of Urology 2012, 19(8), 773-776.
• Clifford SC. Cancer Genetics: Evolution after tumour spread. Nature 2012, 482(7386), 481-482.
• Veal GJ, Boddy AV. Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring. Journal of Clinical Oncology 2012, 30(27), 3424.
• Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, Bomken S, Vormoor J, Hall A, Irving J. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2012, 51(3), 250-256.
• Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, Hewitt L, Huberman K, McNeill HV, Newell DR, Roche C, Ryan-Munden CA, Watson A, Robson CN. Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS One 2012, 7(10), e45539.
• Middleton FK, Chen T, Pollard JR, Curtin NJ. Chemosensitisation By, and Single Agent Activity of, ATR Inhibitor VE-821 in Human Breast Cancer Cells. In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2012, Dublin, Ireland: Pergamon.
• Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson C, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear KA, Slade A, Thommes P, Martin NMB, Newell DR, Smith GCM, Curtin NJ. Chemosensitisation of cancer cells by KU-0060648; a dual inhibitor of DNA-PK and PI-3K. Molecular Cancer Therapeutics 2012, 11(8), 1789-1798.
• Veal GJ, Boddy AV. Chemotherapy in newborns and preterm babies. Seminars in Fetal and Neonatal Medicine 2012, 17(4), 243-248.
• Tennant PWG, Parker L, Thomas JE, Craft AW, Pearce MS. Childhood infectious disease and risk of premature death from cancer: A prospective cohort study. In: 56th Annual Scientific Meeting of the Society for Social Medicine. 2012, London: BMJ Group.
• Hartley AE, Edwards N, Khan F, Playford M, Thomas DJ, Sayer JA. Clinical analysis of a north-east England cystinuria cohort. In: 30th World Congress of Endourology & SWL. 2012, Istanbul, Turkey: Mary Ann Liebert, Inc. Publishers.
• Reedijk A, Kaspers G, Fiocco M, Pession A, Reinhardt D, Zimmermann M, Dworzak M, Alonzo TA, Johnston D, Zapotocky M, De Moerloose B, Finita F, Lee V, Taga T, Tawa A, Auvrignon A, Zeller B, Salgado C, Balwierz W, Popa A, Rubnitz J, Beverloo HBB, Harrison CJ, Gibson B. Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Schwab C, Chilton L, Enshaie A, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Vora AJ, Mitchell CD, Richards SM, Goulden N, Kinsey S, Moorman AV, Harrison CJ. Clinical Relevance of Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL). In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ. Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival. Cancer Research 2012, 72(22), 5675-5682.
• Enciso-Mora V, Hosking FJ, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Tomlinson IPM, Allan JM, Taylor M, Greaves M, Houlston RS. Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 2012, 26(10), 2212-2215.
• Amin S, Walsh M, Wilson C, Parker AE, Oscier D, Willmore E, Mann D, Mann J. Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. Journal of Cellular and Molecular Medicine 2012, 16(9), 2074-2084.
• Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Craft AW, Parker L, de Gonzalez AB. CT scans in childhood and risk of leukaemia and brain tumours reply. Lancet 2012, 380(9855), 1736-1737.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Coy NN, Cook G, Feyler S, Johnson PRE, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA, NCRI Haematological Oncology. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012, 97(3), 442-450.
• Ali S, Sergeant R, O'Brien SG, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood 2012, 120(3), 697-698.
• Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. Defective homologous recombination in human cancers. Cancer Treatment Reviews 2012, 38(2), 89-100.
• Moorman AV, Enshaie A, Chilton L, Schwab C, Tembo T, Richards S, Kinsey S, Vora AJ, Mitchell C, Harrison CJ. Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012, 26, 1829-1841.
• Fiser K, Sieger T, Schumich A, Wood B, Irving J, Mejstrikova E, Dworzak MN. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. Cytometry Part A 2012, 81A(1), 25-34.
• Vasdev N, Kass-Iliyya A, Patel A, Bedford G, O'Riordon A, Johnson MI, Durkan GC, Soomro NA. Developing a laparoscopic radical prostatectomy service: defining the learning curve. Journal of Endourology 2012, 26(7), 903-910.
• Kim KP, Berrington-Gonzalez A, Pearce M, Salotti J, Parker L, McHugh K, Craft A, Lee C. Development of a database of organ doses for pediatric and young adult CT scans in the United Kingdom. Radiation Protection Dosimetry 2012, 150(4), 415-426.
• Giammarioli AM, Gambardella L, Barbati C, Pietraforte D, Tinari A, Alberton M, Gnessi L, Griffin RJ, Minetti M, Malorni W. Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. International Journal of Cancer 2012, 131(4), E337-E347.
• Jones DTW, Jager N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, Wang Q, Lasitschka B, Bartholomae CC, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts MJ, Russell RB, Coco S, Tonini GP, Schuller U, Hans V, Graf N, Kim YJ, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, von Deimling A, Witt O, Maass E, Rossler J, Ebinger M, Schuhmann MU, Fruhwald MC, Hasselblatt M, Jabado N, Rutkowski S, von Bueren AO, Williamson D, Clifford SC, McCabe MG, Collins VP, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott PA, Taylor MD, Meyerson M, Pomeroy SL, Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488(7409), 100-105.
• Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nature Reviews Cancer 2012, 12(12), 801-817.
• Cornell L, Munck J, Curtin N, Reeves H. DNA-PK or ATM inhibition inhibits non-homologous end joining and enhances chemo- and radio sensitivity in hepatocellular cancer cell lines. In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
• Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA, Natl Canc Res Inst. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012, 119(23), 5374-5383.
• Reuillon T, Bertoli A, Griffin RJ, Miller DC, Golding BT. Efficacious N-protection of O-aryl sulfamates with 2,4-dimethoxybenzyl groups. Organic & Biomolecular Chemistry 2012, 10(37), 7610-7617.
• Kumar R, Drinnan M, Mehanna H, Paleri V. Efficacy of the two week wait referral system for head and neck cancer: A systematic review. The Annals of The Royal College of Surgeons of England 2012, 94(3), 101-105.
• Bosomworth HJ, Thornton JK, Coneyworth LJ, Ford D, Valentine RA. Efflux function, tissue-specific expression and intracellular trafficking of the Zn transporter ZnT10 indicate roles in adult Zn homeostasis. Metallomics 2012, 4(8), 771-779.
• Lennard TWJ. Endocrine Surgery. In: Garden, J.O., Bradbury, A.W., Forsythe, J.L.R., Parks, R.W, ed. Principles & Practice of Surgery. Edinburgh: Churchill Livingstone, 2012, pp.325-344.
• Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, Moorman AV, Meyer S, Brown R, Strathdee G. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica 2012, 97(3), 371-378.
• Schwalbe E, Lindsey J, Williamson D, Hamilton D, Northcott P, O'Toole K, Nicholson SL, Lusher M, Gilbertson R, Hauser P, Taylor M, Taylor R, Ellison D, Bailey S, Clifford S. Epigenetic sub-classification and risk-stratification of medulloblastoma using DNA methylomics. In: 15th International Symposium on Pediatric Neuro-Oncology (ISPNO). 2012, Toronto, Canada: Oxford University Press.
• Eyre T, Schwab CJ, Kinstrie R, McGuire AK, Strefford J, Peniket A, Mead A, Littlewood T, Holyoake TL, Copland M, Moorman AV, Harrison CJ, Vyas P. Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood 2012, 120(22), 4441-4443.
• Woolner AF, Davidson A, Skinner R, King D. Evaluation of Infection Control Advice for Patients at Risk of Chemotherapy-Induced Neutropenia in 2 Pediatric Oncology Centers: Cape Town, South Africa, and Newcastle-Upon-Tyne, UK. Pediatric Hematology & Oncology 2012, 29(1), 73-84.
• Reed CD, Launay GG, Carroll MA. Evaluation of tetraethylammonium bicarbonate as a phase-transfer agent in the formation of [¹⁸F]fluoroarenes. Journal of Fluorine Chemistry 2012, 143, 231-237.
• Reed CD, Launay GG, Carroll MA. Evaluation of tetraethylammonium bicarbonate as a phase-transfer agent in the formation of [F-18]fluoroarenes. In: 21st International Isotope Society UK Group Annual Symposium. 2012, Cambridge: John Wiley & Sons Ltd.
• Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJ, James PW, Goodlad JR. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma (HL) aged 60 years or over: the SHIELD study. Blood 2012, 119(25), 6005-6015.
• Vormoor B, Wilkinson S, Harvey F, Plummer R, Curtin N. Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699). In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2012, Dublin, Ireland: Pergamon.
• Farren M, Weston S, Brown H, Broadbent N, Powell S, Shaw R, Smith NR, Inglis R, Graham A, Ashton S, Wedge SR, Barry ST. Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies. Angiogenesis 2012, 15(4), 555-568.
• Basta N, Halliday G, Makin G, Feltbower R, Birch J, Bown N, Elliott M, Ingham D, Moreno L, Barone G, Pearson A, James PW, Tweddle DA, McNally RJQ. Factors associaetd with recurrence and length of survival following relapse in patients with neuroblastoma: a pilot study. In: 44th Congress of the International Society of Paediatric Oncology (SIOP). 2012, London, UK: John Wiley & Sons, Inc.
• Nazarpour K, Barnard A, Jackson A. Flexible cortical control of task-specific muscle synergies. Journal of Neuroscience 2012, 32(36), 12349-12360.
• Arden C, Tudhope SJ, Petrie JL, Al-Oanzi ZH, Cullen KS, Lange AJ, Towle HC, Agius L. Fructose 2,6-bisphosphate is essential for glucose-regulated genetranscription of glucose-6-phosphatase and other ChREBP target genes inhepatocytes. Biochemical Journal 2012, 443(1), 111-123.
• Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemotherapy and Pharmacology 2012, 69(1), 155-164.
• Bieliauskas S, Tubbs RR, Bacon CM, Eshoa C, Foucar K, Gibson SE, Kroft SH, Sohani AR, Swerdlow SH, Cook JR. Gamma Heavy-chain Disease: Defining the Spectrum of Associated Lymphoproliferative Disorders Through Analysis of 13 Cases. American Journal of Surgical Pathology 2012, 36(4), 534-543.
• Sinclair JC, Davies KM, Venien-Bryan C, Noble MEM. Generation of protein lattices by fusing proteins with matching rotational symmetry. Nature Nanotechnology 2012, 6(9), 558-562.
• Schwab C, Chilton L, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Moorman AV, Harrison CJ. Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL) Are Associated with Major Cytogenetic Subgroups. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Anstee QM, Darlay R, Leathart JB, Clement J, Clement K, Aithal GP, Valenti L, Van Gaal L, Stickel F, Allison ME, Romero-Gomez M, Andrade RJ, Reeves H, Pihlajamaki J, Bedossa P, Kotronen A, Yki-Jarvinen H, Chalasani NP, Kleiner DE, Rotter J, Burt AD, Ratziu V, Cordell HJ, Daly AK, Day CP. Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD. In: 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). 2012, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
• Harrison CJ. Genomic Analysis Drives Tailored Therapy in Poor Risk Childhood Leukemia. Cancer Cell 2012, 22(2), 139-140.
• Bechmann LP, Gastaldelli A, Vetter D, Patman GL, Pascoe L, Hannivoort RA, Lee UE, Fiel I, Muñoz U, Ciociaro D, Buzzigoli E, Miele L, Hui KY, Bugianesi E, Burt AD, Day CP, Mari A, Agius L, Walker M, Friedman SL, Reeves HL. Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity and non alcoholic fatty liver disease. Hepatology 2012, 55(4), 1083-1093.
• Allan J, Sniehotta F, Johnston M. Good planners can already plan but poor planners benefit from action plans. In: “Resiliance and Health” : 26th Conference of the European Health Psychology Society. 2012, Prague, Czech Republic: Routledge.
• McCann LJ, McPartland J, Barge D, Strain L, Calonje E, Verbov J, Riordan A, Bourn D, Wright M, Bacon C, Kokai G, Abinun M. Granulomatous inflammation at presentation of severe T cell immunodeficiency due to RMRP mutation (cartilage-hair hypoplasis). In: 15th Biennial Meeting European Society for Immunodeficiency (ESID). 2012, Florence, Italy: Springer.
• Snowden JA, Pearce RM, Lee J, Kirkland K, Gilleece M, Veys P, Clark RE, Kazmi M, Abinun M, Jackson GH, Mackinnon S, Russell NH, Cook G, BSBMT Clinical Trials Comm. Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. British Journal of Haematology 2012, 157(6), 742-746.
• Willmore E, Rodrigues N, Allinson L, Summerfield GP, Wallis J, Lowe C, Curtin N. High Activity of Poly(ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Wilkinson S, Van Noorden S, Bradburn A, Banda K, Chagaluka G, Griffin B, Lampert I, Bailey S, Bacon C, Molyneux E, Rand V. High-resolution genome-wide analysis of endemic Burkitt Lymphoma using DNA extracted from fine-needle aspirates preserved at ambient temperature. In: 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkins Lymphoma. 2012, New York, USA: Wiley-Blackwell Publishing Ltd.
• Pearce MS, Mann KD, Relton CL, Francis RM, Steele JG, Craft AW, Parker L. How the Newcastle Thousand Families birth cohort study has contributed to the understanding of the impact of birth weight and early life socioeconomic position on disease in later life. Maturitas 2012, 72(1), 23-28.
• Williamson SC, Hepburn AC, Wilson L, Coffey K, Ryan-Munden CA, Pal D, Leung HY, Robson CN, Heer R. Human α₂β₁^HI CD133^+VE Epithelial Prostate Stem Cells Express Low Levels of Active Androgen Receptor. PLoS One 2012, 7(11), e48944.
• Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Bjork-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R. Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology 2012, 30(26), 3187-3193.
• Maggina P, Stroud C, Bourne H, Cole T, Collin M, Jackson G, Flood T, Barge D, Mansfield J, Hodges S, Spickett G, Gennery A. Idiopathic colitis following haematopoietic stem cell transplantation for chronic granulomatous disease: Three cases at a national centre. In: 15th Biennial Meeting European Society for Immunodeficiency (ESID). 2012, Florence, Italy: Springer.
• Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Masic D, Patel B, Rowe JM, Tallman M, Goldstone AH, Fielding AK, Harrison CJ. IGH@ Translocations, CRLF2 Deregulation and Microdeletions in Adolescents and Adults with Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2012, 30(25), 3100-3108.
• Rabin KR, Mason CC, Gurusiddappa S, Leung HCE, Morrison DJ, Bhojwani D, Barnette P, South ST, Miles RR, Devidas M, Pession A, Basso G, Potter NE, Kearney L, Moorman AV, Raimondi SC, Jeha S, Pui CH, Carroll WL, Loh ML, Hunger SP, Mullighan CG, Schiffman JD. IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, Whitcher B, Clarke L, Plummer R, Judson I, Jones R, Alonzi R, Brunner T, Koh DM, Murphy P, Waterton JC, Parker G, Graves MJ, Scheenen TWJ, Redpath TW, Orton M, Karczmar G, Huisman H, Barentsz J, Padhani A, Expt Canc Med Ctr Imaging Network. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology 2012, 22(7), 1451-1464.
• Russell LJ, Jones L, Erhorn A, Ensahei A, Masic D, Bentley H, Laczko KS, Harrison CJ. Immunoglobulin Heavy Chain Locus (IGH@) Translocations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Incidence and Risk Stratification. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• O'Neill KA, Bunch KJ, Vincent TJ, Spector LG, Moorman AV, Murphy MFG. Immunophenotype and Cytogenetic Characteristics in the Relationship Between Birth Weight and Childhood Leukemia. Pediatric Blood & Cancer 2012, 58(1), 7-11.
• Kaloriti D, Tillmann A, Jacobsen M, Yin Z, Patterson M, Radmaneshfar E, You T, Chandrasekaran K, Pang W, Coghill G, de Moura APS, Thiel M, Romano MC, Grebogi C, Haynes K, Quinn J, Gow NAR, Brown AJP. Impact of combinatorial stresses upon Candida albicans. In: 18th Congress of the International Society for Human and Animal Mycology. 2012, Berlin, Germany: Wiley-Blackwell Verlag GmbH.
• Rogers AG, Darné A, Soomro NA. Incidental metastatic endocrine tumor diagnosed at laparoscopic radical prostatectomy and bilateral lymph node dissection. Indian Journal of Urology 2012, 28(3), 353-356.
• Alferez DG, Goodlad RA, Odedra R, Sini P, Crafter C, Ryan AJ, Wedge SR, Wright NA, Anderson E, Wilkinson RW. Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia. International Journal of Oncology 2012, 41(4), 1475-1485.
• Stone SJ, Paleri V, Staines KS. Internal carotid artery aneurysm presenting as dental and orofacial pain. Journal of Laryngology and Otology 2012, 126(8), 851-853.
• Cross P, Naik R, Patel A, Nayar A, Hemming J, Williamson S, Henry J, Edmondson RJ, Godfrey KA, Galaal K, Metin A, Lopes A. Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience. BJOG 2012, 119(7), 896-897.
• Harrison CJ, Moorman AV, Schwab C, Heerema NA, Carroll AJ, Haas OA. Intrachromosomal Amplification of Chromosome 21(iAMP21): Cytogenetic Characterisation and Outcome in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL). A Study On Behalf of the Ponte Di Legno International Childhood ALL Workshop. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Shaw H, Larkin J, Corrie P, Ellis S, Nobes J, Marshall E, Kumar S, Danson S, Plummer R, Nathan P. Ipilimumab for advanced melanoma in an expanded access programme (EAP): Ocular, mucosal and acral subtype UK experience. In: 37th Congress of the European Society for Medical Oncology (ESMO). 2012, Vienna, Austria: Oxford University Press.
• Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabro L, De Rossi C, Di Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunology, Immunotherapy 2012, 61(1), 41-48.
• Herriott A, Sweeney M, Whitaker M, Taggart M, Huang JY. Kinetochore localised Mad2 and Cdc20 is itself insufficient for triggering the mitotic checkpoint when Mps1 is low in Drosophila melanogaster neuroblasts . Cell Cycle 2012, 11(24), 4650-4660.
• Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2012, 26(2), 296-302.
• Hui KYD, Robinson S, Patman GL, Manas D, Reeves HL, White S. KLF6 splice variant 1 in patients with colorectal liver metastasis correlates with a higher clinical risk score. In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
• Patman GL, Hui KY, Anstee QM, Reeves HL. Kruppel-like factor 6 splice variant 3 (KLF6-SV3) - The redox sensitive splice variant of KLF6 expressed in non-alcoholic steatohepatitis (NASH). In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL). 2012, Barcelona, Spain: Elsevier BV.
• Elder AK, Heidenreich O, Vormoor HJ. Lentiviralmarking as a tool to investigate the clonal complexity and evolution of ALL. In: Annual Meeting of the Kind-Philipp Foundation for Leukemia Research. 2012, Wilsede, Lueneburg Heath, Germany: Georg Thieme Verlag.
• Vormoor J, Chintagumpala M. Leukaemia & cancer in neonates. Seminars in Fetal & Neonatal Medicine 2012, 17(4), 183-184.
• Van Der Veer A, Waanders E, Pieters R, Willemse ME, Reijmersdaal S, Russell LJ, Harrison CJ, Evans WE, van der Velden VHJ, Hoogerbrugge PM, van Leeuwen FN, Escherich G, Horstman M, Khankandani LM, Rizopoulos D, de Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. Leukemia Cells with a BCR-ABL1-Like signature and/or IKZF1 deletions, but Not High CRLF2 Expression, Are Predictive of an Unfavorable Prognosis in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Williamson C, Blackwood JK, Greaves L, Wilson L, Pickard RS, Lako M, Robson CN, Turnbull DM, Taylor RW, Heer R. Lineage tracking in situ: Where are the prostate stem cells? What are they doing?. In: Annual Meeting of the Society of Academic and Research Surgery. 2012, Nottingham, UK: John Wiley & Sons Ltd.
• Jorgensen M, Cheng D, Goulden N, Vora A, Shankar A, Hough R, Grandage V, Samarasinghe S. Low efficacy of routine CSF surveillance in detecting asymptomatic CNS relapse in children with acute lymphoblastic leukaemia. In: 44th Congress of the International Society of Paediatric Oncology (SIOP). 2012, London, UK: John Wiley & Sons, Inc.
• Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TSY, Kim SK, Ra YS, Fangusaro J, Korshunov A, Toledano H, Nakamura H, Hayden JT, Chan J, Lafay-Cousin L, Hu PZ, Fan X, Muraszko KM, Pomeroy SL, Lau CC, Ng HK, Jones C, Van Meter T, Clifford SC, Eberhart C, Gajjar A, Pfister SM, Grundy RG, Huang A. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncology 2012, 13(8), 838-848.
• Zhang ZL, Tian C, Zhou SX, Wang W, Guo Y, Xia J, Liu ZM, Wang BA, Wang XW, Golding BT, Griffin RJ, Du YS, Liu JY. Mechanism-based design, synthesis and biological studies of N-5-substituted tetrahydrofolate analogs as inhibitors of cobalamin-dependent methionine synthase and potential anticancer agents. European Journal of Medicinal Chemistry 2012, 58, 228-236.
• Televantou D, Hui KYD, Lochan R, Charnley R, Burt AD, Reeves HL. Membranous expression of sulfatase-2 is associated with a poorer prognosis in patients following pancreatic cancer resection. In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
• Kontny NE, Boos J, Wurthwein G, Hempel G, Boddy AV, Groll AH, Krischke M. Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring: Focus on IV Drug Administration. Therapeutic Drug Monitoring 2012, 34(4), 460-466.
• Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrcz-Krzemien S, Rocha V, Mohty M. Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 2012, 18(9), 1422-1429.
• Cowell IG, Sondka Z, Smith K, Lee KC, Manville CM, Sidorczuk-Lesthuruge M, Rance HA, Padget K, Jackson GH, Adachi N, Austin CA. Model for MLL translocations in therapy-related leukemia involving topoisomerase II beta-mediated DNA strand breaks and gene proximity. Proceedings of the National Academy of Sciences 2012, 109(23), 8989-8994.
• Finlay MRV, Griffin RJ. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorganic & Medicinal Chemistry Letters 2012, 22(17), 5352-5359.
• Kool M, Korshunov A, Remke M, Jones DTW, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, Backlund ML, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison DW, Gilbertson RJ, Pomeroy SL, Taylor MD, Lichter P, Pfister SM. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica 2012, 123(4), 473-484.
• Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica 2012, 123(4), 465-472.
• Thakur IR, Ensor H, Jesson J, Eyre L, Hancock J, Harrison C, Morman A, Lawson S, Flow MRD Lab Network, Mol MRD Lab Network. Molecular versus flow cytometric MRD analysis - is there an explanation for discrepancies?. In: 52nd Annual Scientific Meeting of the British Society for Haematology. 2012, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
• Lee KC, Padget K, Curtis Hannah, Cowell IG, Moiani D, Sondka Z, Morris NK, Jackson GH, Cockell SJ, Tainer JA, Austin CA. MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA. Biology Open 2012, 1(9), 863-873.
• Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed H, O'Toole K, Nicholson SL, Bognar L, Garami M, Hauser P, Korshunov A, Pfister SM, Williamson D, Taylor RE, Ellison DW, Bailey S, Clifford SC. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathologica 2012, 123(4), 501-513.
• Gamble LD, Kees UR, Tweddle DA, Lunec J. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene 2012, 31, 752-763.
• Fisher JPH, Tweddle DA. Neonatal neuroblastoma. Seminars in Fetal & Neonatal Medicine 2012, 17(4), 207-215.
• Hunter JE, Willmore E, Irving JAE, Hostomsky Z, Veuger SJ, Durkacz BW. NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene 2012, 31(2), 251-264.
• McCormick A, Curtin NJ, Edmondson RJ. Non homologous end joining assessment in ovarian cancer. In: Blair Bell Research Society Annual Academic Meeting. 2012, London, UK: Wiley-Blackwell Publishing Ltd.
• Biswas S, Lunec J, Bartlett K. Non-glucose metabolism in cancer cells—is it all in the fat?. Cancer and Metastasis Reviews 2012, 31(3-4), 689-698.
• Orienti I, Zuccari G, Falconi M, Teti G, Illingworth NA, Veal GJ. Novel micelles based on amphiphilic branched PEG as carriers for fenretinide. Nanomedicine: Nanotechnology, Biology and Medicine 2012, 8(6), 880-890.
• Gomaa MS, Bridgens CE, Illingworth NA, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold. Bioorganic & Medicinal Chemistry 2012, 20(14), 4201-4207.
• Turner AJ, Knox AA, Watkins NJ. Nucleolar disruption leads to the spatial separation of key 18S rRNA processing factors. RNA Biology 2012, 9(2), 175-186.
• Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S. Of Dogs and Men: Comparative Biology as a Tool for the Discovery of Novel Biomarkers and Drug Development Targets in osteosarcoma. Pediatric Blood & Cancer 2012, 58(3), 327-333.
• Thomas L, Drinnan M, Basavaiah N, Mehanna H, Jones T, Paleri V. Open conservation partial laryngectomy for laryngeal cancer: A Systematic review of English language literature. Cancer Treatment Reviews 2012, 38(3), 203-211.
• Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JPP, Beverloo HB, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, den Boer ML, Zwaan CM. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012, 26(10), 2204-2211.
• Lane J, Slatter M, Nademi Z, Tierney P, Barge D, Hambleton S, Flood T, Cant A, Abinun M, Jackson G, Collin M, Gennery A. Outcome of haematopoietic stem cell transplantation in patients with chronic granulomatous disease at a national centre. In: 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT). 2012, Geneva, Switzerland: Nature Publishing Group.
• Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. British Journal of Haematology 2012, 157(4), 463-471.
• Patman G, Hui KY, Anstee QM, Reeves HL. Oxidative stress induces alternative splicing and nuclear translocation of kruppel like factor 6. In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
• Tudhope SJ, Mulligan EA, Hunter JE, Summerfield GP, Marshall S, Wallis J, Marr H, Evans P, Lowe C, Durkacz BW, Zhang J, Meshulam J, Bobb K, Willmore E. P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Daly AK, Veal GJ, Jamieson D, Coulthard S. Pharmacogenomics research at Newcastle University. Pharmacogenomics 2012, 13(12), 1333-1338.
• Twelves CJ, Nasim M, Anthoney A, Cresti N, Savulsky C, Johnston C, Reyderman L, Wanders J, Plummer R, Evans TRJ. Pharmacokinetics of eribulin mesilate in combination with capecitabine in patients with advanced/metastatic cancer: Results from a phase IB dose-escalation study. In: 37th Congress of the European Society for Medical Oncology (ESMO). 2012, Vienna, Austria: Oxford University Press.
• Savulsky C, Nasim M, Plummer R, Evans J, Morrison R, Anthoney A, Haney S, Madi A, Johnston C, Carter D, Reydermann L, Gopalakrishna P, Wanders J, Twelves C. Phase Ib dose-escalation study of eribulin in combination with capecitabine in patients with advanced/metastatic cancer. In: Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Onkologie. 2012, Stuttgart, Germany: S. Karger AG.
• Curtin NJ. Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors. Drug Discovery Today: Disease Models 2012, 9(2), e51-e58.
• Clapham KM, Rennison T, Jones G, Craven F, Bardos J, Golding BT, Griffin RJ, Haggerty K, Hardcastle IR, Thommes P, Ting A, Cano C. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives. Organic & Biomolecular Chemistry 2012, 10(33), 6747-6757.
• Cork DMW, Lennard TWJ, Tyson-Capper AJ. Progesterone receptor (PR) variants exist in breast cancer cells characterised as PR negative. Tumor Biology 2012, 33(6), 2329-2340.
• Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Craft AW, Parker L, de Gonzalez AB. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. The Lancet 2012, 380(9840), 499-505.
• Sultan J, Griffin SM, Di Franco F, Kirby JA, Shenton BK, Seal CJ, Davis P, Viswanath YKS, Preston SR, Hayes N. Randomized clinical trial of omega-3 fatty acid-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing oesophagogastric cancer surgery. British Journal of Surgery 2012, 99(3), 346-355.
• Challen C, Anderson JJ, Chrzanowska-Lightowlers ZMA, Lightowlers R, Lunec J. Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA. International Journal of Oncology 2012, 40(3), 851-859.
• Sturgess K, Slatter M, Bigley V, Dickinson R, Haniffa M, McGovern N, Jardine L, Jackson G, Cant A, Gennery A, Hambleton S, Collin M. Reduced-intensity haematopoietic stem cell transplant rescues immune function and corrects pulmonary alveolar proteinosis in DCML deficiency/GATA 2 mutation. In: 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT). 2012, Geneva, Switzerland: Nature Publishing Group.
• Coffey K, Robson CN. Regulation of the androgen receptor by post-translational modifications. Journal of Endocrinology 2012, 215(2), 221-237.
• Rigas AC, Williamson SC, Kennedy A, El-Sherif A, Soomro NA, Brown CDA, Robson CN, Heer R. Renal differentiation from adult spermatogonial stem cells. In: Annual Meeting of the Society of Academic and Research Surgery. 2012, Nottingham, UK: John Wiley & Sons Ltd.
• Mehanna H, McQueen A, Robinson M, Paleri V. Salivary gland swellings. British Medical Journal 2012, 345, e6794.
• Bomken S, Dhir S, Windebank K, Skinner R. Salvage of multiply relapsed Burkitt's non-Hodgkin lymphoma by matched-unrelated donor haematopoietic stem cell transplantation. In: 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkins Lymphoma. 2012, New York, USA: Wiley-Blackwell Publishing Ltd.
• Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD. Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Journal of the National Cancer Institute 2012, 104(5), 357-370.
• Pawlyn C, Davies FE, Gregory WM, Szubert AJ, Bell SE, Ouzman J, Drayson MT, Owen RG, Jackson GH, Russell NH, Morgan GJ. Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Hepburn AC, Veeratterapillay R, Williamson SC, El-Sherif A, Sahay N, Thomas HD, Mantilla A, Pickard RS, Robson CN, Heer R. Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling. PLoS One 2012, 7(11), e50690.
• McNally RJ, Blakey K, Parslow RC, James PW, Gomez-Pozo B, Stiller C, Vincent TJ, Norman P, McKinney PA, Murphy MF, Craft AW, Feltbower RG. Small area analyses of bone cancer diagnosed in 0-49 year olds from Great Britain provide clues to aetiology. BMC Cancer 2012, 12(1), 270.
• Morak M, Attarbaschi A, Fischer S, Nassimbeni C, Grausenburger R, Bastelberger S, Krentz S, Cario G, Kasper D, Schmitt K, Russell LJ, Potschger U, Stanulla M, Eckert C, Mann G, Haas OA, Panzer-Grumayer R. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. Blood 2012, 120(26), 5134-5142.
• Pearce MS, Salotti JA, McHugh K, Kim KP, Craft AW, Lubin J, Ron E, Parker L. Socio-economic variation in CT scanning in Northern England, 1990-2002. BMC Health Services Research 2012, 12(1), 24.
• Gao ML, Patel R, Ahmad I, Fleming J, Edwards J, McCracken S, Sahadevan K, Seywright M, Norman J, Sansom O, Leung HY. SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Molecular Medicine 2012, 4(8), 776-790.
• Patterson MJ, Murray J, Curtin NJ. Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures). In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2012, Dublin, Ireland: Pergamon.
• Boehringer J, Riedinger C, Paraskevopoulos K, Johnson EOD, Lowe ED, Khoudian C, Smith D, Noble MEM, Gordon C, Endicott JA. Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation. Biochemical Journal 2012, 448(1), 55-65.
• Northcott PA, Shih DJH, Peacock J, Garzia L, Morrissy AS, Zichner T, Stutz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli FMG, Wang X, Remke M, Wu XC, Chiu RYB, Chu A, Chuah E, Corbett RD, Hoad GR, Jackman SD, Li YS, Lo A, Mungall KL, Nip KM, Qian JQ, Raymond AGJ, Thiessen N, Varhol RJ, Birol I, Moore RA, Mungall AJ, Holt R, Kawauchi D, Roussel MF, Kool M, Jones DTW, Witt H, Fernandez-L A, Kenney AM, Wechsler-Reya RJ, Dirks P, Aviv T, Grajkowska WA, Perek-Polnik M, Haberler CC, Delattre O, Reynaud SS, Doz FF, Pernet-Fattet SS, Cho BK, Kim SK, Wang KC, Scheurlen W, Eberhart CG, Fevre-Montange M, Jouvet A, Pollack IF, Fan X, Muraszko KM, Gillespie GY, Di Rocco C, Massimi L, Michiels EMC, Kloosterhof NK, French PJ, Kros JM, Olson JM, Ellenbogen RG, Zitterbart K, Kren L, Thompson RC, Cooper MK, Lach B, McLendon RE, Bigner DD, Fontebasso A, Albrecht S, Jabado N, Lindsey JC, Bailey S, Gupta N, Weiss WA, Bognar L, Klekner A, Van Meter TE, Kumabe T, Tominaga T, Elbabaa SK, Leonard JR, Rubin JB, Liau LM, Van Meir EG, Fouladi M, Nakamura H, Cinalli G, Garami M, Hauser P, Saad AG, Iolascon A, Jung S, Carlotti CG, Vibhakar R, Ra YS, Robinson S, Zollo M, Faria CC, Chan JA, Levy ML, Sorensen PHB, Meyerson M, Pomeroy SL, Cho YJ, Bader GD, Tabori U, Hawkins CE, Bouffet E, Scherer SW, Rutka JT, Malkin D, Clifford SC, Jones SJM, Korbel JO, Pfister SM, Marra MA, Taylor MD. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012, 488(7409), 49-56.
• Alhasan SF, Beale GS, Newell DR, Reeves HL. Suppression of SULF2, an extracellular endosulfatase up-regulated in hepatocellular cancers, modulates WNT signalling and inhibits cell growth. In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
• Rogers HA, Kilday JP, Mayne C, Ward J, Adamowicz-Brice M, Schwalbe EC, Clifford SC, Coyle B, Grundy RG. Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathologica 2012, 123(5), 711-725.
• Gomaa MS, Lim AST, Wilson-Lau SC, Watts AM, Illingworth NA, Bridgens CE, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates. Bioorganic & Medicinal Chemistry 2012, 20(20), 6080-6088.
• Shao H, Abbas AY, Shi S, Foley D, Huang S, Bradshaw TD, Pepper C, Endicott JA, Wang S, Fischer PM. Synthesis and in Vitro Evaluation of Selective CDK9 Inhibitors. In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2012, Dublin, Ireland: Pergamon.
• Ramsay C, Pickard R, Robertson C, Close A, Vale L, Armstrong N, Barocas DA, Eden CG, Fraser C, Gurung T, Jenkinson D, Jia X, Lam TB, Mowatt G, Nea DE, Robinson MC, Royle J, Rushton SP, Sharma P, Shirley MDF, Soomro N. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technology Assessment 2012, 16(41), xiv, 313.
• Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discovery Today 2012, 17(5-6), 194-202.
• Axon A, May FEB, Gaughan LE, Williams FM, Blain PG, Wright MC. Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity. Toxicology 2012, 298(1-3), 40-51.
• Ahmed ARH, Griffiths AB, Tilby MT, Westley BR, May FEB. TFF3 Is a Normal Breast Epithelial Protein and Is Associated with Differentiated Phenotype in Early Breast Cancer but Predisposes to Invasion and Metastasis in Advanced Disease. American Journal of Pathology 2012, 180(3), 904-916.
• Baumli S, Hole AJ, Noble MEM, Endicott JA. The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508. ACS chemical biology 2012, 7(5), 811-816.
• Baumli S, Hole AJ, Wang LZ, Noble MEM, Endicott JA. The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b. Structure 2012, 20(10), 1788-1795.
• Ataman OU, Sambrook SJ, Wilks C, Lloyd A, Taylor AE, Wedge SR. The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective. International Journal of Radiation Oncology - Biology - Physics 2012, 84(4), e447–e454.
• Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Reviews 2012, 26(3), 123-135.
• Armstrong JL, Martin S, Illingworth NA, Jamieson D, Neilson A, Lovat PE, Redfern CPF, Veal GJ. The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide. Oncology Reports 2012, 27(1), 293-298.
• Brioli A, Ross FM, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen RG, Jackson GH, Cavo M, Davies FE, Morgan GJ. The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Fisher J, Mitra D, Price L, Lewis J, Johnstone H, Gerrard A, Hale J, Clifford SC, Bailey S. The importance of biopsy following radiological diagnosis of relapsed medulloblastoma. British Journal of Neurosurgery 2012, 26(4), 542-544.
• Dolan B, Naughton J, Tegtmeyer N, May FEB, Clyne M. The Interaction of Helicobacter pylori with the Adherent Mucus Gel Layer Secreted by Polarized HT29-MTX-E12 Cells. PLoS One 2012, 7(10), e47300.
• Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, Cialfi S, Vergalli J, Fragliasso V, Guerzoni C, Manzotti G, Soliera AR, Menin C, Bertorelle R, McDowell HP, Inserra A, Belli ML, Varesio L, Tweddle D, Tonini GP, Altavista P, Dominici C, Raschellà G, Calabretta B. The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform. Neoplasia 2012, 14(7), 634-643.
• May FEB. The potential of trefoil proteins as biomarkers in human cancer. Biomarkers in Medicine 2012, 6(3), 301-304.
• Biswas S, Rankin KS, Long A, Jackson J, Howard R, Nisar S, Birch M, Lunec J. The prognostic role of MT1-MMP and HIF Isoforms in Human Osteosarcoma. In: American Association for Cancer Research (AACR). 2012, Chicago, Illinois, USA.
• Townes CL, Ali A, Lanz M, Gross N, Robson CN, Hall J, Pickard RS. The protective antimicrobial effect of raised prostate specific antigen levels during male urinary tract infection. In: 27th Annual Congress of the European Association of Urology. 2012, Paris, France: Elsevier BV.
• Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, Creutzig U, Klingebiel T. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012, 97(1), 21-29.
• Jorgensen M, Shankar A, Aabideen Z, Cheng D, Goulden N, Vora A, Grandage V, Hough R, Samarasinghe S. The role of routine surveillance for silent central nervous system relapse in children with acute lymphoblastic leukaemia. British Journal of Haematology 2012, 159(3), 368-370.
• Endicott JA, Noble MEM, Johnson LN. The Structural Basis for Control of Eukaryotic Protein Kinases. Annual Review of Biochemistry 2012, 81, 587-613.
• Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal of Cancer 2012, 106(8), 1386-1394.
• Medina B, Paraskevopoulos K, Boehringer J, Sznajder A, Robertson M, Endicott J, Gordon C. The ubiquitin-associated (UBA) 1 domain of Schizosaccharomyces pombe Rhp23 is essential for the recognition of ubiquitin-proteasome system substrates both in Vitro and in Vivo. Journal of Biological Chemistry 2012, 287(50), 42344-42351.
• Shall S, Gaymes T, Farzaneh F, Curtin N, Mufti GJ. The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients. In: Tulin, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2012, pp.239-66.
• Jarvis IWH, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ. Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours. Biochemical Pharmacology 2012, 83(1), 69-77.
• Lennard TWJ. Total Thyroidectomy, Lymph Node Dissection for Cancer. In: Fischer, J.E, ed. Fischer's Mastery of Surgery. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins, 2012, pp.479-485.
• Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor HM, te Kronnie T, Bradtke J, Mann G, Vendramini E, Palmi C, Schwab C, Russell LJ, Schrappe M, Conter V, Mitchell CD, Strehl S, Zimmermann M, Potschger U, Harrison CJ, Stanulla M, Panzer-Grumayer R, Haas OA, Moorman AV, Assoc Italiana Ematologia Oncologi, Natl Canc Res Inst NCRI-Childrens. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology 2012, 158(6), 772-777.
• Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast 2012, 21(1), 20-26.
• de Jong A, Merkx R, Berlin I, Rodenko B, Wijdeven RHM, El Atmioui D, Yalcin Z, Robson CN, Neefjes JJ, Ovaa H. Ubiquitin-Based Probes Prepared by Total Synthesis To Profile the Activity of Deubiquitinating Enzymes. ChemBioChem 2012, 13(15), 2251-2258.
• Plummer R. Understanding failure of PARP inhibition in the clinic. In: 10th International Symposium on Targeted Anticancer Therapies. 2012, Amsterdam, Netherlands: Oxford University Press.
• Biggar MA, Lennard TWJ. Urgent parathyroidectomy. ANZ Journal of Surgery 2012, 82(4), 193-194.
• Bate J, Chisholm J, Skinner R, Breuer J, Ramsay M, Wheatley K, Hambleton S, Heath PT. Varicella post-exposure prophylaxis in children with cancer: urgent need for a randomised controlled trial. Archives of Disease in Childhood 2012, 97(9), 853-854.
• Spagnolo L, Barbeau J, Curtin NJ, Morris EP, Pearl LH. Visualization of a DNA-PK/PARP1 complex. Nucleic Acids Research 2012, 40(9), 4168-4177.
• Paleri V, Carding P, Chatterjee S, Kelly C, Wilson JA, Welch A, Drinnan M. Voice outcomes after concurrent chemoradiotherapy for advanced nonlaryngeal head and neck cancer: A prospective study. Head and Neck 2012, 34(12), 1747-1752.